Meet the team that lives life science to support your growth and success.

Deepak Behera is a highly accomplished physician-scientist and strategist with over two decades of leadership experience in the medical, academic, and pharmaceutical sectors. His proficiency in medical affairs, clinical development, and radiopharmaceuticals, has been pivotal to the successful launch and commercialization of two industry-leading products.

His early clinical experience grounded him in practical insights before transitioning to academic translational research at Stanford University. His work at Stanford led to birth of two startups, five early-phase trials, and the co-authorship of two patents, highlighting his innovative approach to nuclear medicine.

Deepak’s transition to the pharmaceutical industry was marked by his impactful roles as Senior Medical Director, Head of Medical Affairs, Strategic Medical Director, and Chief Medical Officer. These positions saw him navigate complex clinical development landscapes, Phase I-III study designs, FDA interactions, and oversee the successful launch of two commercial products. Having worked collaboratively with American, European and Asian companies, Deepak is culturally sensitive and adaptable in a global medical landscape.

As a scholar, Deepak has enriched the medical discourse with over 20 peer-reviewed articles and 15 impactful lectures and presentations. His dedication to the medical community extends beyond his professional roles, as demonstrated by his active involvement in organizations like Adaptive Research, EPPIC Global, IASNM, and MISI. As an industry pioneer, Deepak’s embodies the seamless blend of medical expertise, innovative research, commercial understanding and strategic leadership in medical affairs and radiopharmaceuticals.

As a seasoned executive in healthcare operations, patient engagement and strategy, Martin has held various leadership roles, all of which included managing teams and driving growth across both clinical and commercial operations. His expertise also includes patient recruitment and retention, strategic planning, execution, process optimization, and product design and development.

Most recently, Martin was the Head of Strategy and Innovation for the commercial engagement services at IQVIA. In this role he led the design and development of digitized patient services, partnering with Apple and Samsung, and oversaw the integration of their digital patient platform. He also developed and implemented the business plan for IQVIA’s digital patient engagement solution, led product development, expanded business development opportunities, and engineered a digital patient recruitment solution. Before joining IQVIA Martin was a senior executive at PRA Health Sciences as the insourced manager at Bayer Healthcare, responsible for developing patient engagement and recruitment strategies, partnering with third-party vendors, and assessing and qualifying the vendor management process.

As the Vice President of Operations, Bioclinica (now Clario) Martin was responsible for patient recruitment and retention where he provided leadership to the patient recruitment division, restructured operations post-acquisition, launched a patient recruitment platform, and developed a siteless clinical trial solution in collaboration with major pharmaceutical companies. At Hitachi Data Systems Martin was Manager of Life Sciences, business development, responsible for accelerating growth of sales and revenues for healthcare and life sciences solutions.

In addition to his leadership roles in healthcare operations, Martin held various senior executive roles in finance, more notably, CFO of Axis Healthcare, (now Huntsworth Health) and global finance direction for Wolters Kluwer. His role included directing the post-acquisition integration and reorganization of the finance and accounting departments, managing the transitioning to new accounting software, implementing a new chart of accounts, and establishing month-end close process and reporting.

Martin holds a Master of Science (MSc) in professional accountancy from the University of London, School of Economics and is a fellow of the Association of Chartered Certified Accountants (ACCA) in the UK.

Dr. Evelhoch is a distinguished expert in quantitative medical imaging and its use in drug development, with more than 40 years’ experience in imaging and over 20 years in biopharmaceutical research. He has been instrumental in identifying, validating and translating to the clinic quantitative imaging biomarkers for the pathophysiological effects of cancer therapeutics and detection of tau pathology in the earliest stages of Alzheimer’s Disease. As an accomplished author, Dr. Evelhoch has published influential papers that enhance the understanding of how imaging biomarkers can be used to inform critical decisions during the development of new drugs.

Dr. Evelhoch retired from Merck as Vice President and Head of Translational Biomarkers. In that role he led a group of 100 scientists, with expertise in quantitative imaging and molecular assays and was responsible for the development and qualification of novel biomarkers used to inform pipeline decisions and the development and deployment of companion diagnostic tests. Prior to joining Merck, he held positions as Executive Director and Head of Imaging Sciences at Amgen and Director of Structural Imaging at Pfizer. Before entering the biopharmaceutical industry, he served as a Professor of Internal Medicine, Oncology, and Radiology at Wayne State University, focusing on quantitative imaging techniques to assess tumor physiology and treatment response.

Dr. David Krause is Principal, Delta Pharmaceutical Consulting.  A broadly experienced pharmaceutical executive, Dr. Krause is board-certified in internal medicine with added qualifications in geriatrics. Dr. Krause has more than 30 years of experience in pharmaceutical research and development and medical affairs. He has successfully led clinical development and medical affairs teams at large and medium-sized public entities and small private start-ups.  He successfully filed multiple BLAs and NDAs. Dr. Krause led clinical development of several global therapeutic areas at SmithKline Beecham and GlaxoSmithKline. He was then Chief Medical Officer at Vicuron Pharmaceuticals, which was later acquired by Pfizer, Inc. Most recently he served as Chief Medical Officer at Genomind, Inc., a private, venture-funded pharmacogenetic testing and medication management company. In addition to clinical development and medical affairs, his expertise includes business development.

Dr. Krause is a Fellow of the American College of Physicians, and author of dozens of scientific publications and numerous abstracts. He has served as a consultant to the Department of Defense, and is a member of Genomind’s Scientific Advisory Board.  

Dr. Krause is a graduate of the Pennsylvania State University, where he received BAs in Art History and Psychology. He was also named a Centennial Fellow by the College of Liberal Arts. He received his MD degree from Temple University, where he completed his residency in internal medicine.

In his spare time Dr. Krause is a landscape photographer.

Jon is an entrepreneurial-minded scientist with over 20 years of research and development experience in the pharma and biotech industry (spanning GSK, Eli Lilly and SynOA Therapeutics). While at GSK he was focused on osteoarthritis therapeutic development through leading and shaping corporate strategy and employing both biologics and small molecule-based approaches to discover and progress clinical candidates. At GSK, Jon’s lab discovered and progressed two molecules to the candidate selection milestone. Thereafter, he led the clinical development effort as Early Development Leader providing experience in drafting protocols and informed consents, investigator brochures as well as regulatory IND submissions and application of Good Clinical Practice guidelines. Jon received his PhD in Pathology and Cell Biology from Thomas Jefferson University where he studied hepatitis B virus immunopathology and the effects of antiviral drug treatment and alcohol consumption on viral replication and gene expression in a novel HBV SCID mouse model he developed.

An accomplished pharmaceutical and biotechnology leader, Dr. Lumsden brings a mix of large and small company experience across U.S. and international markets. Recognized as a networker and team-builder, he has successfully built companies from scratch through IPOs, gaining a deep understanding of capital markets and delivering shareholder value.
Always focused on saving and/or improving patient lives, Dr. Lumsden has worked in many therapeutic areas, including infectious diseases, osteoporosis, women’s health, cardio- renal disease, oncology and inflammation/immunology.

Initially a practicing large animal veterinarian, he was recruited by Merck & Co., Inc. to assist in the U.K launch of IVOMEC (ivermectin). Dr. Lumsden relocated to the U.S. to lead the launch of GASTROGARD (omeprazole) for equines, the first new product launch at the newly formed Merial. Transitioning to human health, global responsibilities at Merck included CRIXIVAN (indinavir), FOSAMAX (alendronate) and NUVARING (etonogestrel/ethinyl estradiol). Leading cross-functional teams gave Dr. Lumsden experience across commercialization, clinical and non-clinical development, regulatory, CMC, finance, intellectual property, patent litigation and governmental affairs. He played a key role on the integration team during the acquisition by Merck of Schering Plough (SP), concluding in global responsibility for one of the legacy SP businesses.

His experience in the biotechnology world started with an opportunity to lead Motif Bio from a medicinal chemistry base, building a team from scratch, through the acquisition of a clinical stage antibacterial, iclaprim, completing two IPOs, raising over $125 million from the public markets, the successful completion of two Phase 3 clinical studies and submission of an NDA to FDA. Broad and deep experience of M&A was gained seeking commercialization partners and in-license candidates. Additional CEO and Board experience at private biotechnology companies has encompassed fund-raising, corporate restructuring, financial audits, cap table cleansing, and recruitment/management of CROs (clinical and non-clinical).

Dr. Lumsden is currently a member of the Board of Directors at Kibow Therapeutics, Inc., a profitable consumer and veterinary microbiome therapeutics business with a live biotherapeutic product in Phase 2 clinical development for patients with Stage 4 CKD.

With over forty years of experience in oncology and nuclear medicine, Dr. McEwan is a world-renowned expert in his field. Most recently, he was Chief Medical Officer at Ariceum, a company developing novel medicines for systemic targeted radiotherapy (SRT), and immediately prior to that he was Vice President of Radiopharmaceuticals at Ipsen. As an academic physician, Dr. McEwan served as Chair of the Departments of Radiology and Oncology at the University of Alberta. Dr. McEwan has worked as a physician at Alberta Health Services for over thirty years, with additional postings that have included Clinical Director of the Cross Cancer Institute and Clinical Head of Diagnostic Imaging at the University of Alberta Hospital. Dr. McEwan has authored over 120 publications in oncology and radiopharmaceuticals and SRT.

David Raunig is an accomplished leader in data science and drug development with over 28 years of experience in medical, scientific, and statistical innovation. He has been instrumental in guiding clinical trials from Phase 0 through IIb, playing a critical role in designing Statistical and Biomarker Analysis Plans for FDA and EMA submissions. Notably, David contributed to the development of five FDA-validated study biomarkers and led disease progression model development across oncology, neurodegeneration, and GI transit, among other therapeutic areas. 

With over 40 years of increasing leadership responsibility, David has held executive positions overseeing strategic planning, business development, and governance. His leadership has earned them multiple awards for team engagement and turnaround, mentoring junior and senior personnel who have achieved accelerated promotions. Additionally, David has fostered collaborations with top Key Opinion Leaders (KOLs) and prestigious institutions, such as WUSTL, Columbia University, and Johns Hopkins, while contributing to scientific and statistical advisory boards. 

Wil worked for over 35 years in clinical imaging as a Professor of Radiology, initially at the Mallinckrodt Institute in St Louis and then Temple University in Philadelphia before switching to industry and spending 5 years as a Medical Director of Icon Medical Imaging. He received an MBA from Washington University, Olin School of Business in 2000.  He has expertise and has published extensively in medical imaging, the development of magnetic resonance imaging (MRI) techniques and optimization of other imaging modalities to improve understanding of disease processes such as traumatic brain injury, stroke, and musculoskeletal disorders. As a practicing physician, Wil has been involved with clinical trials both from the clinical and the CRO sides with a specific focus on imaging endpoints. 

Ina Margaretha is based in Amsterdam and has a 25 years of experience with the fields of clinical drug development, strategic partnerships, business development, and building innovative biotech businesses and CROs in Europe.

Ina Margaretha has been developing business plans for start-ups, organizing funding (including European grants), leading R&D programs, outsourcing development and commercial strategies to develop groundbreaking therapies in the field of immunology, allergy, inflammatory diseases (including post-COVID), musculoskeletal, orphan diseases and CNS, ultimately negotiating attractive licensing deals to accelerate time to market. She has also experience in gene and cell therapies and combined medical devices.

Over the course of her career, she has created strong relationships with life science investors, built strong scientific and operational teams, and developed long term partnerships with biopharma partners to bring innovative treatments to patients.

Ina Margaretha has a Master’s Degree in Biomedical Sciences from the Leiden University Medical Centre, The Netherlands.

Andrew (Andy) brings more than 40 years’ experience in the biotech/pharmaceutical industry having initiated and built several biotech companies including Inotek Pharmaceuticals Corporation, Radikal Therapeutics, Salzman Group, Chilmark Laboratories, and Orphan Technologies, where he oversaw the entire spectrum of drug development activities, including discovery chemistry, pharmacology, and preclinical activities, manufacturing, clinical Phase I-II, as well as the US and international regulatory strategies. Andy has over 170 peer-reviewed articles, 47 patents, and was the inventor and development lead for the clinical-stage PARP-1 inhibitor. More recently Andy’s focus and interest has been on the clinical use of cannabinoids.

Rosemary has extensive sales and marketing experience in Medical Imaging, Software, Drug Development, Medical Devices, Oncology, Neuromuscular, Musculoskeletal and Metabolic diseases. With her demonstrated history in Executive Leadership, Business Development, Sales Growth, and Marketing in the medical device and pharmaceutical development industries, Rosemary excels at preparing and delivering presentations to investors as well as Board of Director members.  

As a results-oriented executive, Nick has a strong track record of success in team building, strategic planning, and tactical execution in pharma, biotech, and medical device organizations. Previously Nick’s extensive experience includes senior executive positions at Merck, Merial and Reliefband providing him expertise with global drug, dietary supplements, nutraceuticals, biologicals, and med device development and commercialization experience. He is a serial entrepreneur taking companies from start up through financing stages to exit. Nick was the founder, Chairman, and CEO of Topaz Pharmaceuticals, the founder and managing partner of Humanitas Consulting, the co-founder of Reliefband Technologies, a med device company as well as co-founder of BioVeras – bringing blockchain to life sciences. In addition, Nick has served for 10 years as an Adjunct Professor at the University of the Sciences, Philadelphia, specializing in pharmaceutical, biotech and med device entrepreneurship, marketing, and commercialization as well as direct involvement with the PA Biotechnology Center, Doylestown, since 2005.

Brad is a recognized expert with more than 25 years of experience in clinical trial design. His extensive experience includes a 10-year tenure at Pfizer, where he played a pivotal role in developing and implementing imaging biomarkers in clinical studies across multiple therapeutic areas. Formerly, he held the position of Vice President of Imaging and Clinical Development at ImaginAb. In this role, he was responsible for the development and clinical testing of novel PET tracers. Currently, Brad collaborates with medical device and biotech companies, providing consultancy services to implement innovative biomarkers and design robust, data-driven studies. His expertise is invaluable in guiding through critical go/no-go development decisions, ensuring they are made based on solid, actionable insights.